Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S.

Vertex Pharmaceuticals has a dominant Cystic fibrosis franchise and plans to launch five new products by 2028, including a next-generation CF drug and a non-opioid pain management drug. VRTX stock has ...

The stock has fallen from a peak back in April. In recent years, the biotech has expanded into other treatment areas, even scoring regulatory approval for a gene editing therapy for blood disorders ...

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue growth.

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain ...